Urological Research

, Volume 19, Issue 1, pp 45–50 | Cite as

Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer

A flow cytofluorometric analysis
  • E. C. de Boer
  • W. H. de Jong
  • A. P. M. van der Meijden
  • P. A. Steerenberg
  • F. Witjes
  • P. D. J. Vegt
  • F. M. J. Debruyne
  • E. J. Ruitenberg
Original Articles

Summary

Cellular immunologic reactions occurring in the bladder after intravesical treatment with bacillus Calmette-Guérin (BCG) were investigated by flow cytofluorometric analysis of leukocytes present in the urine. Urine specimens from 11 superficial bladder cancer patients were collected before and 5, 24, 48 and 72 h after repeated BCG instillations. Monoclonal antibodies specific for granulocytes, monocytes/macrophages, and T-and B-lymphocytes were used to characterize and quantify leukocyte subpopulations. The total number of cells in urine was found to be 2- to 485-fold increased 24 h after BCG administration. The predominant cell type present was the polymorphonuclear granulocyte, probably representing a defense mechanism against mycobacteria. The main mononuclear leukocytes in urine specimens were monocytes/macrophages and T-lymphocytes, indicating an ongoing immune response in the bladder wall. Although percentages of lymphocytes were low, T- and B-cells could be identified using a selective cell measurement procedure. In conclusion, a clear increase in the numbers of granulocytes, monocytes/macrophages and T-lymphocytes in urine after intravesical BCG administration was demonstrated, indicating local activation of the immune system.

Key words

Intravesical BCG therapy Bladder cancer Urine sediment Flow cytofluorometry Cellular immunological reaction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antony VB, Sahn SA, Antony AC, Repine JE (1985) Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 76:1514Google Scholar
  2. 2.
    Becker EL (1988) The cytotoxic action of neutrophils on mammalian cells in vitro. Prog Allergy 40:183Google Scholar
  3. 3.
    Böhle A, Nowc C, Ulmer A, Musehold J, Flad F (1989) Detection of urinary IL-1, IL-2, and TNF after intravesical BCG therapy. Paper presented at conference “New trends in urology”, September 13–16, 1989, University of Nijmegen; (Abstract book p 40)Google Scholar
  4. 4.
    Davies M (1982) Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system. Biochem Biophys Acta 651:143Google Scholar
  5. 5.
    Debruyne FMJ, Van Der Meijden APM, Geboers ADH, Franssen MPH, Van Leeuwen MJW, Steerenberg PA, De Jong WH, Ruitenberg EJ (1988) BCG-RIVM versus mitomycin intraversical therapy in superficial bladder cancer. First results of a randomized prospective trial. Urology 31 [Suppl]:20Google Scholar
  6. 6.
    De Jong WH, De Boer EC, Van Der Meijden APM, Vegt P, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1990) Presence of interleukin-2 in urine after intravesical treatment of superficial bladder cancer patients with bacillus Calmette-Guérin. Cancer Immunol Immunother 31:182Google Scholar
  7. 7.
    De Jong WH, Steerenberg PA, Ruitenberg EJ (1987) Bacillus Calmette-Guérin (BCG) and its use for cancer immunotherapy. Res Monogr Immunol 11:283Google Scholar
  8. 8.
    Guinan P, Shaw M, Ray P (1986) Histopathology of BCG and thiotepa treated bladders. Urol Res 14:211Google Scholar
  9. 9.
    Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Uro 136:970Google Scholar
  10. 10.
    Haaf EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ (1985) Role of immunotherapy in the prevention of reccurrence and invasion of urothelial bladder tumors: a review. World J Urol 3:76Google Scholar
  11. 11.
    Holzer TJ, Kizlaitis L, Vachula M, Weaver CW, Andersen BR (1988) Human phagocytic cell responses to Mycobacterium leprae and Mycobacterum bovis Bacillus Calmette-Guérin. J Immunol 141:170Google Scholar
  12. 12.
    Huland E, Huland H (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469Google Scholar
  13. 13.
    Lage JM, Bauer WC, Kelley DR, Ratliff TL, Catalona WJ (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guérin treatment of superficial bladder cancer. J Urol 135:916Google Scholar
  14. 14.
    Montgomery LG, Lemon WS (1933) The cellular reaction of the pleura to infection with myobacteria tuberculosis. J Thoracic Surg 2:429Google Scholar
  15. 15.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180Google Scholar
  16. 16.
    Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63:264Google Scholar
  17. 17.
    Ratliff TL (1989) Mechanisms of action of intravesical BCG for bladder cancer. In: Debruyne FMJ, Denis L, Van Der Meijden APM (eds) BCG in superficial bladder cancer. EORTC Genitourinary group monograph 6. Liss, New York, p 107Google Scholar
  18. 18.
    Segasothy M, Lau TM, Birch DF, Fairley KF, Kincaid-Smith P (1988) Immunocytologic dissection of the urine sediment using monoclonal antibodies. Am J Clin Pathol 90:961Google Scholar
  19. 19.
    Stefanini GF, Bercovich E, Mazzeo V, Grigioni WF, Emili E, D'Errico A, Lo Cigno M, Tamagnini N, Mazetti M (1989) Class I and Class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment. J Urol 141:1449Google Scholar
  20. 20.
    Van der Meijden APM, De Jong WH, Steerenberg PA, Walvoort HC, De Boer EC, Debruyne FMJ, Ruitenberg EJ (1988) Intravesical BCG administration in the guniea pig. A histomorphological study. Virchows Arch [B] 55:207Google Scholar
  21. 21.
    Weiner RS, Linn R, Wasjman Z, Hackett RL (1989) Identification of T subpopulation in human bladder washings during a six week course of intravesical BCG (abstract 487). AUA 84th Annual Meeting, May 7–11, 1989, Dallas. J Urol 141:291AGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • E. C. de Boer
    • 1
  • W. H. de Jong
    • 1
  • A. P. M. van der Meijden
    • 2
    • 3
  • P. A. Steerenberg
    • 1
  • F. Witjes
    • 2
  • P. D. J. Vegt
    • 4
  • F. M. J. Debruyne
    • 2
  • E. J. Ruitenberg
    • 5
  1. 1.Laboratory for PathologyNational Institute of Public Health and Environmental Protection (RIVM)BilthovenThe Netherlands
  2. 2.Department of UrologyUniversity Hospital NijmegenNijmegenThe Netherlands
  3. 3.Department of Urology's-HertogenboschThe Netherlands
  4. 4.Department of UrologySt. Elisabeth HospitalLeiderdorpThe Netherlands
  5. 5.Central Laboratory of the Red Cross Blood Transfusion ServiceAmsterdamThe Netherlands

Personalised recommendations